PremiumThe FlyProtara Therapeutics reports Q1 EPS (29c), consensus (48c) Biotech Alert: Searches spiking for these stocks today Protara Therapeutics’ TARA-002: Promising Phase 2 Results and Market Potential in NMIBC Treatment PremiumThe FlyProtara Therapeutics appoints Leonardo Viana Nicacio as chief medical officer Protara Therapeutics’ TARA-002 Shows Promising Potential in NMIBC Treatment, Justifying Buy Rating Protara Therapeutics announces presentation of results from THRIVE-1 study PremiumCompany AnnouncementsProtara Therapeutics Reports Progress and Financial Results Protara Therapeutics reports Q4 EPS (48c) vs (90c) last year TARA Earnings this Week: How Will it Perform? 
